ICU Medical, Inc. $ICUI Shares Sold by Granite Investment Partners LLC

Granite Investment Partners LLC reduced its position in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 14.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 77,167 shares of the medical instruments supplier’s stock after selling 12,585 shares during the quarter. Granite Investment Partners LLC’s holdings in ICU Medical were worth $9,257,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Syon Capital LLC purchased a new position in ICU Medical during the third quarter worth approximately $241,000. GSA Capital Partners LLP purchased a new position in shares of ICU Medical during the 3rd quarter valued at approximately $381,000. State of New Jersey Common Pension Fund D lifted its position in shares of ICU Medical by 21.3% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 17,471 shares of the medical instruments supplier’s stock valued at $2,096,000 after buying an additional 3,064 shares in the last quarter. Public Sector Pension Investment Board grew its stake in ICU Medical by 14.8% in the 3rd quarter. Public Sector Pension Investment Board now owns 96,270 shares of the medical instruments supplier’s stock valued at $11,549,000 after acquiring an additional 12,412 shares during the period. Finally, Caprock Group LLC purchased a new stake in ICU Medical in the 3rd quarter worth $757,000. Hedge funds and other institutional investors own 96.10% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on ICUI shares. KeyCorp upped their price objective on shares of ICU Medical from $175.00 to $180.00 and gave the stock an “overweight” rating in a research report on Friday. Piper Sandler boosted their target price on shares of ICU Medical from $172.00 to $178.00 and gave the stock an “overweight” rating in a research note on Friday. Wall Street Zen raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Sunday, February 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of ICU Medical in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $179.33.

ICU Medical Stock Performance

NASDAQ:ICUI opened at $157.03 on Monday. The company has a market cap of $3.88 billion, a P/E ratio of 7,855.43 and a beta of 0.79. ICU Medical, Inc. has a twelve month low of $107.00 and a twelve month high of $164.35. The company’s 50-day moving average price is $149.40 and its 200-day moving average price is $135.99. The company has a current ratio of 2.39, a quick ratio of 1.15 and a debt-to-equity ratio of 0.60.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Thursday, February 19th. The medical instruments supplier reported $1.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.68 by $0.23. The company had revenue of $535.94 million during the quarter, compared to analysts’ expectations of $541.20 million. ICU Medical had a net margin of 0.03% and a return on equity of 7.33%. ICU Medical’s revenue was down 14.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.11 EPS. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. On average, sell-side analysts forecast that ICU Medical, Inc. will post 4.11 earnings per share for the current fiscal year.

Key Stories Impacting ICU Medical

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Q4 EPS beat street estimates — ICU Medical reported $1.91 EPS vs. the consensus $1.68, a surprise on the bottom line that helped lift sentiment. Earnings and Revenues Surpass Estimates
• Positive Sentiment: Company raised FY2026 EPS guidance to a range of $7.75–$8.45, above the consensus ~7.41, signaling confidence in the outlook and likely supporting the rally. Company Press Release
• Positive Sentiment: Sell-side support: Piper Sandler reiterated a Buy rating, which can sustain investor demand following results. Piper Sandler Rating
• Neutral Sentiment: Board action to extend an executive severance plan was announced as a measure to preserve leadership stability — governance/retention detail that reduces execution risk but is not a direct earnings driver. Severance Plan Extension
• Neutral Sentiment: Company published the earnings slide deck and call transcript for investors to review management commentary and details on margins, supply chain and demand trends. Earnings Call Transcript
• Negative Sentiment: Revenue slightly missed expectations at $535.94M vs. $541.20M est. and was down ~14% year‑over‑year, highlighting ongoing demand weakness that investors will watch for reversal. Q4 Results and Guidance
• Negative Sentiment: Profitability pressure: EPS declined from $2.11 a year ago to $1.91 and the company reported a slightly negative net margin, underscoring margin and volume headwinds. Investor Presentation / Press Release

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.